Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).Kristina M. Jordahl, Safiyyah Ziyad, Ethan Thompson et al.|Journal of Clinical Oncology|2025Cited by 1
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)Safiyyah Ziyad, Jesús G. Berdeja, Kristina M. Jordahl et al.|Blood|2025Cited by 0